Celltrion, Inc. (068270.KS)
KSE · KRW · Healthcare · Biotechnology
₩188,600 (-0.74%) as of
Key statistics
- Market cap
- 43.00T
- Forward P/E
- 24.74
- Dividend yield
- 0.38%
- 52-week range
- 158,500.00 – 239,047.62
- Beta
- 0.28
- Revenue (TTM)
- 4.9T
- Profit margin
- 32.18%
- Analyst target
- ₩269,303.03
- Volume
- 471.81k
About Celltrion, Inc.
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Incheon, South Korea
- Employees
- 2,956
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.